Access the full text.
Sign up today, get DeepDyve free for 14 days.
( Schäfer-KortingMBlechschmidtJKortingH. Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. Mycoses 1996; 39: 329–339.9009654)
Schäfer-KortingMBlechschmidtJKortingH. Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. Mycoses 1996; 39: 329–339.9009654Schäfer-KortingMBlechschmidtJKortingH. Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. Mycoses 1996; 39: 329–339.9009654, Schäfer-KortingMBlechschmidtJKortingH. Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. Mycoses 1996; 39: 329–339.9009654
(2008)
allows isoenzyme-specific inhibitor screening
C. Rwenyonyi, A. Kutesa, L. Muwazi, I. Okullo, A. Kasangaki, Addy Kekitinwa (2011)
Oral Manifestations in HIV/AIDS-Infected ChildrenEuropean Journal of Dentistry, 5
( EnwuruCAOgunledunAIdikaN, et al. Fluconazole resistant opportunistic oro-pharyngeal candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. Afr Health Sci 2008; 8: 142–148.19357740)
EnwuruCAOgunledunAIdikaN, et al. Fluconazole resistant opportunistic oro-pharyngeal candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. Afr Health Sci 2008; 8: 142–148.19357740EnwuruCAOgunledunAIdikaN, et al. Fluconazole resistant opportunistic oro-pharyngeal candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. Afr Health Sci 2008; 8: 142–148.19357740, EnwuruCAOgunledunAIdikaN, et al. Fluconazole resistant opportunistic oro-pharyngeal candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria. Afr Health Sci 2008; 8: 142–148.19357740
( OksalaE. Factors predisposing to oral yeast infections. Acta Odontol Scand 1990; 48: 71–74.2181813)
OksalaE. Factors predisposing to oral yeast infections. Acta Odontol Scand 1990; 48: 71–74.2181813OksalaE. Factors predisposing to oral yeast infections. Acta Odontol Scand 1990; 48: 71–74.2181813, OksalaE. Factors predisposing to oral yeast infections. Acta Odontol Scand 1990; 48: 71–74.2181813
M. Pfaller, A. Houston, S. Coffmann (1996)
Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrataJournal of Clinical Microbiology, 34
( MashudaFZuechnerAChalyaPL, et al. Pattern and factors associated with congenital anomalies among young infants admitted at Bugando medical centre, Mwanza, Tanzania. BMC Res Notes 2014; 7: 1–7.24382056)
MashudaFZuechnerAChalyaPL, et al. Pattern and factors associated with congenital anomalies among young infants admitted at Bugando medical centre, Mwanza, Tanzania. BMC Res Notes 2014; 7: 1–7.24382056MashudaFZuechnerAChalyaPL, et al. Pattern and factors associated with congenital anomalies among young infants admitted at Bugando medical centre, Mwanza, Tanzania. BMC Res Notes 2014; 7: 1–7.24382056, MashudaFZuechnerAChalyaPL, et al. Pattern and factors associated with congenital anomalies among young infants admitted at Bugando medical centre, Mwanza, Tanzania. BMC Res Notes 2014; 7: 1–7.24382056
( MushiMFNgetaNMiramboMM, et al. Predictors of esophageal candidiasis among patients attending endoscopy unit in a tertiary hospital, Tanzania: a retrospective cross-sectional study. Afr Health Sci 2018; 18: 66–71.29977259)
MushiMFNgetaNMiramboMM, et al. Predictors of esophageal candidiasis among patients attending endoscopy unit in a tertiary hospital, Tanzania: a retrospective cross-sectional study. Afr Health Sci 2018; 18: 66–71.29977259MushiMFNgetaNMiramboMM, et al. Predictors of esophageal candidiasis among patients attending endoscopy unit in a tertiary hospital, Tanzania: a retrospective cross-sectional study. Afr Health Sci 2018; 18: 66–71.29977259, MushiMFNgetaNMiramboMM, et al. Predictors of esophageal candidiasis among patients attending endoscopy unit in a tertiary hospital, Tanzania: a retrospective cross-sectional study. Afr Health Sci 2018; 18: 66–71.29977259
( TahaTEGrahamSMKumwendaNI, et al. Morbidity among human immunodeficiency virus-1-infected and-uninfected African children. Pediatrics 2000; 106: e77.)
TahaTEGrahamSMKumwendaNI, et al. Morbidity among human immunodeficiency virus-1-infected and-uninfected African children. Pediatrics 2000; 106: e77.TahaTEGrahamSMKumwendaNI, et al. Morbidity among human immunodeficiency virus-1-infected and-uninfected African children. Pediatrics 2000; 106: e77., TahaTEGrahamSMKumwendaNI, et al. Morbidity among human immunodeficiency virus-1-infected and-uninfected African children. Pediatrics 2000; 106: e77.
( PetersenPEBourgeoisDOgawaH, et al. The global burden of oral diseases and risks to oral health. Bull World Health Organ 2005; 83: 661–669.16211157)
PetersenPEBourgeoisDOgawaH, et al. The global burden of oral diseases and risks to oral health. Bull World Health Organ 2005; 83: 661–669.16211157PetersenPEBourgeoisDOgawaH, et al. The global burden of oral diseases and risks to oral health. Bull World Health Organ 2005; 83: 661–669.16211157, PetersenPEBourgeoisDOgawaH, et al. The global burden of oral diseases and risks to oral health. Bull World Health Organ 2005; 83: 661–669.16211157
( WilcoxCMStraubRFClarkWS. Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration. Am J Gastroenterol 1995; 90: 1938–1941.7484995)
WilcoxCMStraubRFClarkWS. Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration. Am J Gastroenterol 1995; 90: 1938–1941.7484995WilcoxCMStraubRFClarkWS. Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration. Am J Gastroenterol 1995; 90: 1938–1941.7484995, WilcoxCMStraubRFClarkWS. Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration. Am J Gastroenterol 1995; 90: 1938–1941.7484995
M. Mushi, O. Bader, Christine Bii, U. Groß, S. Mshana (2018)
Virulence and susceptibility patterns of clinical Candida spp. isolates from a tertiary hospital, Tanzania.Medical mycology
M. Mushi, Conjester Mtemisika, O. Bader, Christine Bii, M. Mirambo, U. Groß, S. Mshana (2016)
High Oral Carriage of Non-albicans Candida spp. among HIV-infected individuals.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 49
( BelaziMVelegrakiAKoussidou-EremondiT, et al. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment. Oral Microbiol Immunol 2004; 19: 347–351.15491459)
BelaziMVelegrakiAKoussidou-EremondiT, et al. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment. Oral Microbiol Immunol 2004; 19: 347–351.15491459BelaziMVelegrakiAKoussidou-EremondiT, et al. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment. Oral Microbiol Immunol 2004; 19: 347–351.15491459, BelaziMVelegrakiAKoussidou-EremondiT, et al. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment. Oral Microbiol Immunol 2004; 19: 347–351.15491459
M. Arendrup, M. Cuenca‐Estrella, C. Lass‐Flörl, W. Hope (2012)
EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST).Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 18 7
( FongIWManuelLBurford-MasonA. Asymptomatic oral carriage of Candida albicans in patients with HIV infection. Clin Invest Med 1997; 20: 85–93.9088664)
FongIWManuelLBurford-MasonA. Asymptomatic oral carriage of Candida albicans in patients with HIV infection. Clin Invest Med 1997; 20: 85–93.9088664FongIWManuelLBurford-MasonA. Asymptomatic oral carriage of Candida albicans in patients with HIV infection. Clin Invest Med 1997; 20: 85–93.9088664, FongIWManuelLBurford-MasonA. Asymptomatic oral carriage of Candida albicans in patients with HIV infection. Clin Invest Med 1997; 20: 85–93.9088664
( EUCAST. The European Committee on Antimicrobial Susceptibility Testing, http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_6.0_Breakpoint_table.pdf (accessed 1 January 2016).)
EUCAST. The European Committee on Antimicrobial Susceptibility Testing, http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_6.0_Breakpoint_table.pdf (accessed 1 January 2016).EUCAST. The European Committee on Antimicrobial Susceptibility Testing, http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_6.0_Breakpoint_table.pdf (accessed 1 January 2016)., EUCAST. The European Committee on Antimicrobial Susceptibility Testing, http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_6.0_Breakpoint_table.pdf (accessed 1 January 2016).
( AlbertsonGDNiimiMCannonRD, et al. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 1996; 40: 2835–2841.9124851)
AlbertsonGDNiimiMCannonRD, et al. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 1996; 40: 2835–2841.9124851AlbertsonGDNiimiMCannonRD, et al. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 1996; 40: 2835–2841.9124851, AlbertsonGDNiimiMCannonRD, et al. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 1996; 40: 2835–2841.9124851
F. Barchiesi, D. Arzeni, M. Prete, A. Sinicco, L. Francesco, M. Pasticci, L. Lamura, M. Nuzzo, F. Burzacchini, S. Coppola, F. Chiodo, G. Scalise (1998)
Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis.The Journal of antimicrobial chemotherapy, 41 5
( MushiMFBaderOTaverne-GhadwalL, et al. Oral candidiasis among African human immunodeficiency virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan Africa. J Oral Microbiol 2017; 9: 1317579.28748027)
MushiMFBaderOTaverne-GhadwalL, et al. Oral candidiasis among African human immunodeficiency virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan Africa. J Oral Microbiol 2017; 9: 1317579.28748027MushiMFBaderOTaverne-GhadwalL, et al. Oral candidiasis among African human immunodeficiency virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan Africa. J Oral Microbiol 2017; 9: 1317579.28748027, MushiMFBaderOTaverne-GhadwalL, et al. Oral candidiasis among African human immunodeficiency virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan Africa. J Oral Microbiol 2017; 9: 1317579.28748027
( PfallerMDiekemaDRexJ, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819–826.16517860)
PfallerMDiekemaDRexJ, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819–826.16517860PfallerMDiekemaDRexJ, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819–826.16517860, PfallerMDiekemaDRexJ, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819–826.16517860
( AhmedMMHokororoAKidenyaBR, et al. Prevalence of undernutrition and risk factors of severe undernutrition among children admitted to Bugando medical centre in Mwanza, Tanzania. BMC Nutrition 2016; 2: 49.)
AhmedMMHokororoAKidenyaBR, et al. Prevalence of undernutrition and risk factors of severe undernutrition among children admitted to Bugando medical centre in Mwanza, Tanzania. BMC Nutrition 2016; 2: 49.AhmedMMHokororoAKidenyaBR, et al. Prevalence of undernutrition and risk factors of severe undernutrition among children admitted to Bugando medical centre in Mwanza, Tanzania. BMC Nutrition 2016; 2: 49., AhmedMMHokororoAKidenyaBR, et al. Prevalence of undernutrition and risk factors of severe undernutrition among children admitted to Bugando medical centre in Mwanza, Tanzania. BMC Nutrition 2016; 2: 49.
( CartledgeJDMidgleyJGazzardBG. Non-albicans oral candidosis in HIV-positive patients. J Antimicrob Chemother 1999; 43: 419–422.10223601)
CartledgeJDMidgleyJGazzardBG. Non-albicans oral candidosis in HIV-positive patients. J Antimicrob Chemother 1999; 43: 419–422.10223601CartledgeJDMidgleyJGazzardBG. Non-albicans oral candidosis in HIV-positive patients. J Antimicrob Chemother 1999; 43: 419–422.10223601, CartledgeJDMidgleyJGazzardBG. Non-albicans oral candidosis in HIV-positive patients. J Antimicrob Chemother 1999; 43: 419–422.10223601
( KumarCGKumarSSJMenonT. Phospholipase and proteinase activities of clinical isolates of Candida from immunocompromised patients. Mycopathologia 2006; 161: 213–218.16552483)
KumarCGKumarSSJMenonT. Phospholipase and proteinase activities of clinical isolates of Candida from immunocompromised patients. Mycopathologia 2006; 161: 213–218.16552483KumarCGKumarSSJMenonT. Phospholipase and proteinase activities of clinical isolates of Candida from immunocompromised patients. Mycopathologia 2006; 161: 213–218.16552483, KumarCGKumarSSJMenonT. Phospholipase and proteinase activities of clinical isolates of Candida from immunocompromised patients. Mycopathologia 2006; 161: 213–218.16552483
( PfallerMAHoustonACoffmannS. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J Clin Microbiol 1996; 34: 58–61.8748273)
PfallerMAHoustonACoffmannS. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J Clin Microbiol 1996; 34: 58–61.8748273PfallerMAHoustonACoffmannS. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J Clin Microbiol 1996; 34: 58–61.8748273, PfallerMAHoustonACoffmannS. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J Clin Microbiol 1996; 34: 58–61.8748273
( PfallerMBoykenLHollisR, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150–156.18032613)
PfallerMBoykenLHollisR, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150–156.18032613PfallerMBoykenLHollisR, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150–156.18032613, PfallerMBoykenLHollisR, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150–156.18032613
( BernhardMWeigMZautnerAE, et al. Yeast On-Target Lysis (YOTL), a procedure for making auxiliary mass spectrum data sets for clinical routine identification of yeasts. J Clin Microbiol 2014; 52: 4163–4167.25232169)
BernhardMWeigMZautnerAE, et al. Yeast On-Target Lysis (YOTL), a procedure for making auxiliary mass spectrum data sets for clinical routine identification of yeasts. J Clin Microbiol 2014; 52: 4163–4167.25232169BernhardMWeigMZautnerAE, et al. Yeast On-Target Lysis (YOTL), a procedure for making auxiliary mass spectrum data sets for clinical routine identification of yeasts. J Clin Microbiol 2014; 52: 4163–4167.25232169, BernhardMWeigMZautnerAE, et al. Yeast On-Target Lysis (YOTL), a procedure for making auxiliary mass spectrum data sets for clinical routine identification of yeasts. J Clin Microbiol 2014; 52: 4163–4167.25232169
C. Enwuru, A. Ogunledun, N. Idika, Enwuru Nv, F. Ogbonna, M. Aniedobe, A. Adeiga (2008)
Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria.African health sciences, 8 3
E. Oksala (1990)
Factors predisposing to oral yeast infections.Acta odontologica Scandinavica, 48 1
( AmbroseEEMakaniJChamiN, et al. High birth prevalence of sickle cell disease in Northwestern Tanzania. Pediatr Blood Cancer 2018; 65: e26735.)
AmbroseEEMakaniJChamiN, et al. High birth prevalence of sickle cell disease in Northwestern Tanzania. Pediatr Blood Cancer 2018; 65: e26735.AmbroseEEMakaniJChamiN, et al. High birth prevalence of sickle cell disease in Northwestern Tanzania. Pediatr Blood Cancer 2018; 65: e26735., AmbroseEEMakaniJChamiN, et al. High birth prevalence of sickle cell disease in Northwestern Tanzania. Pediatr Blood Cancer 2018; 65: e26735.
( PfallerMMesserSBoykenL, et al. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46: 3518–3521.12384359)
PfallerMMesserSBoykenL, et al. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46: 3518–3521.12384359PfallerMMesserSBoykenL, et al. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46: 3518–3521.12384359, PfallerMMesserSBoykenL, et al. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46: 3518–3521.12384359
( AkpanAMorganR. Oral candidiasis. Postgrad Med J 2002; 78: 455–459.12185216)
AkpanAMorganR. Oral candidiasis. Postgrad Med J 2002; 78: 455–459.12185216AkpanAMorganR. Oral candidiasis. Postgrad Med J 2002; 78: 455–459.12185216, AkpanAMorganR. Oral candidiasis. Postgrad Med J 2002; 78: 455–459.12185216
P. Petersen, D. Bourgeois, H. Ogawa, S. Estupiñán-Day, C. Ndiaye (2005)
The global burden of oral diseases and risks to oral health.Bulletin of the World Health Organization, 83 9
C. Wilcox, R. Straub, W. Clark (1995)
Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration.The American journal of gastroenterology, 90 11
( BlignautEBotesMENiemanHL. The treatment of oral candidiasis in a cohort of South African HIV/AIDS patients. SADJ 1999; 54: 605–608.16892568)
BlignautEBotesMENiemanHL. The treatment of oral candidiasis in a cohort of South African HIV/AIDS patients. SADJ 1999; 54: 605–608.16892568BlignautEBotesMENiemanHL. The treatment of oral candidiasis in a cohort of South African HIV/AIDS patients. SADJ 1999; 54: 605–608.16892568, BlignautEBotesMENiemanHL. The treatment of oral candidiasis in a cohort of South African HIV/AIDS patients. SADJ 1999; 54: 605–608.16892568
( PatilSRaoRSMajumdarB, et al. Clinical appearance of oral Candida infection and therapeutic strategies. Front Microbiol 2015; 6: 1391.)
PatilSRaoRSMajumdarB, et al. Clinical appearance of oral Candida infection and therapeutic strategies. Front Microbiol 2015; 6: 1391.PatilSRaoRSMajumdarB, et al. Clinical appearance of oral Candida infection and therapeutic strategies. Front Microbiol 2015; 6: 1391., PatilSRaoRSMajumdarB, et al. Clinical appearance of oral Candida infection and therapeutic strategies. Front Microbiol 2015; 6: 1391.
M. Niimi, N. Firth, R. Cannon (2010)
Antifungal drug resistance of oral fungiOdontology, 98
E. Blignaut, Botes Me, Nieman Hl (1999)
The treatment of oral candidiasis in a cohort of South African HIV/AIDS patients.SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging, 54 12
M. Pfaller, D. Diekema, J. Rex, A. Espinel-Ingroff, E. Johnson, D. Andes, V. Chaturvedi, M. Ghannoum, F. Odds, M. Rinaldi, D. Sheehan, P. Troke, T. Walsh, D. Warnock (2006)
Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive BreakpointsJournal of Clinical Microbiology, 44
( OzturkMAGunesTKokluE, et al. Oral nystatin prophylaxis to prevent invasive candidiasis in neonatal intensive care unit. Mycoses 2006; 49: 484–492.17022766)
OzturkMAGunesTKokluE, et al. Oral nystatin prophylaxis to prevent invasive candidiasis in neonatal intensive care unit. Mycoses 2006; 49: 484–492.17022766OzturkMAGunesTKokluE, et al. Oral nystatin prophylaxis to prevent invasive candidiasis in neonatal intensive care unit. Mycoses 2006; 49: 484–492.17022766, OzturkMAGunesTKokluE, et al. Oral nystatin prophylaxis to prevent invasive candidiasis in neonatal intensive care unit. Mycoses 2006; 49: 484–492.17022766
M. Mushi, O. Bader, L. Taverne-Ghadwal, Christine Bii, U. Groß, S. Mshana (2017)
Oral candidiasis among African human immunodeficiency virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan AfricaJournal of Oral Microbiology, 9
M. Pfaller, S. Messer, L. Boyken, H. Huynh, R. Hollis, D. Diekema (2002)
In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of Candida spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing MethodsAntimicrobial Agents and Chemotherapy, 46
T. Taha, Stephen Graham, N. Kumwenda, Robin Broadhead, D. Hoover, D. Markakis, L. Hoeven, G. Liomba, J. Chiphangwi, P. Miotti (2000)
Morbidity among human immunodeficiency virus-1-infected and -uninfected African children.Pediatrics, 106 6
( MushiMFMasewaBJandeM, et al. Prevalence and factor associated with over-the-counter use of antifungal agents’, in Mwanza City, Tanzania. Tanzania J Health Res 2017; 19: 1–8.)
MushiMFMasewaBJandeM, et al. Prevalence and factor associated with over-the-counter use of antifungal agents’, in Mwanza City, Tanzania. Tanzania J Health Res 2017; 19: 1–8.MushiMFMasewaBJandeM, et al. Prevalence and factor associated with over-the-counter use of antifungal agents’, in Mwanza City, Tanzania. Tanzania J Health Res 2017; 19: 1–8., MushiMFMasewaBJandeM, et al. Prevalence and factor associated with over-the-counter use of antifungal agents’, in Mwanza City, Tanzania. Tanzania J Health Res 2017; 19: 1–8.
( ThanyasrisungPKesakomolPPipattanagovitP, et al. Oral Candida carriage and immune status in Thai human immunodeficiency virus-infected individuals. J Med Microbiol 2014; 63: 753–759.24591706)
ThanyasrisungPKesakomolPPipattanagovitP, et al. Oral Candida carriage and immune status in Thai human immunodeficiency virus-infected individuals. J Med Microbiol 2014; 63: 753–759.24591706ThanyasrisungPKesakomolPPipattanagovitP, et al. Oral Candida carriage and immune status in Thai human immunodeficiency virus-infected individuals. J Med Microbiol 2014; 63: 753–759.24591706, ThanyasrisungPKesakomolPPipattanagovitP, et al. Oral Candida carriage and immune status in Thai human immunodeficiency virus-infected individuals. J Med Microbiol 2014; 63: 753–759.24591706
J. Naglik, Catherine Rodgers, P. Shirlaw, J. Dobbie, L. Fernandes-Naglik, D. Greenspan, N. Agabian, S. Challacombe (2003)
Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections.The Journal of infectious diseases, 188 3
M. Schäfer-Korting, J. Blechschmidt, H. Korting (1996)
Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular riskMycoses, 39
(1999)
Nonalbicans oral candidosis in HIV-positive patients
( HamzaOJMateeMIMoshiMJ, et al. Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol 2008; 8: 135.18694525)
HamzaOJMateeMIMoshiMJ, et al. Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol 2008; 8: 135.18694525HamzaOJMateeMIMoshiMJ, et al. Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol 2008; 8: 135.18694525, HamzaOJMateeMIMoshiMJ, et al. Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol 2008; 8: 135.18694525
( WilliamsDWLewisMAO. Oral Microbiology: isolation and identification of Candida from the oral cavity. Oral Dis 2000; 6: 3–11.10673781)
WilliamsDWLewisMAO. Oral Microbiology: isolation and identification of Candida from the oral cavity. Oral Dis 2000; 6: 3–11.10673781WilliamsDWLewisMAO. Oral Microbiology: isolation and identification of Candida from the oral cavity. Oral Dis 2000; 6: 3–11.10673781, WilliamsDWLewisMAO. Oral Microbiology: isolation and identification of Candida from the oral cavity. Oral Dis 2000; 6: 3–11.10673781
Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans MF Mushi
C. Kumar, Santhosh Kumar, T. Menon (2006)
Phospholipase and Proteinase Activities of Clinical Isolates of Candida from Immunocompromised PatientsMycopathologia, 161
( MushiMFMtemisikaCIBaderO, et al. High oral carriage of non-albicans Candida spp. among HIV-infected individuals. Int J Infect Dis 2016; 49: 185–188.27401585)
MushiMFMtemisikaCIBaderO, et al. High oral carriage of non-albicans Candida spp. among HIV-infected individuals. Int J Infect Dis 2016; 49: 185–188.27401585MushiMFMtemisikaCIBaderO, et al. High oral carriage of non-albicans Candida spp. among HIV-infected individuals. Int J Infect Dis 2016; 49: 185–188.27401585, MushiMFMtemisikaCIBaderO, et al. High oral carriage of non-albicans Candida spp. among HIV-infected individuals. Int J Infect Dis 2016; 49: 185–188.27401585
( RwenyonyiCMKutesaAMuwaziL, et al. Oral manifestations in HIV/AIDS-infected children. Eur J Dent 2011; 5: 291–298.21769270)
RwenyonyiCMKutesaAMuwaziL, et al. Oral manifestations in HIV/AIDS-infected children. Eur J Dent 2011; 5: 291–298.21769270RwenyonyiCMKutesaAMuwaziL, et al. Oral manifestations in HIV/AIDS-infected children. Eur J Dent 2011; 5: 291–298.21769270, RwenyonyiCMKutesaAMuwaziL, et al. Oral manifestations in HIV/AIDS-infected children. Eur J Dent 2011; 5: 291–298.21769270
L. Montes, W. Wilborn (1978)
Oral CandidiasisJournal of Cutaneous Pathology, 5
K. Rhodes (1991)
Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents, 66
I. Fong, M. Laurel, A. Burford-Mason (1997)
Asymptomatic oral carriage of Candida albicans in patients with HIV infection.Clinical and investigative medicine. Medecine clinique et experimentale, 20 2
G. Albertson, M. Niimi, R. Cannon, H. Jenkinson (1996)
Multiple efflux mechanisms are involved in Candida albicans fluconazole resistanceAntimicrobial Agents and Chemotherapy, 40
M. Pfaller, L. Boyken, R. Hollis, J. Kroeger, S. Messer, S. Tendolkar, D. Diekema (2007)
In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global SurveillanceJournal of Clinical Microbiology, 46
M. Belazi, A. Velegraki, T. Koussidou‐Eremondi, Dimitrios Andreadis, S. Hini, G. Arsenis, C. Eliopoulou, E. Destouni, Demetrios Antoniades (2004)
Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment.Oral microbiology and immunology, 19 6
Maimuna Ahmed, A. Hokororo, B. Kidenya, R. Kabyemera, Erasmus Kamugisha (2016)
Prevalence of undernutrition and risk factors of severe undernutrition among children admitted to Bugando Medical Centre in Mwanza, TanzaniaBMC Nutrition, 2
Mareike Bernhard, M. Weig, A. Zautner, U. Groß, O. Bader (2014)
Yeast On-Target Lysis (YOTL), a Procedure for Making Auxiliary Mass Spectrum Data Sets for Clinical Routine Identification of YeastsJournal of Clinical Microbiology, 52
Florentina Mashuda, A. Zuechner, P. Chalya, B. Kidenya, M. Manyama (2014)
Pattern and factors associated with congenital anomalies among young infants admitted at Bugando medical centre, Mwanza, TanzaniaBMC Research Notes, 7
( GokceGCerikciogluNYagciA. Acid proteinase, phospholipase, and biofilm production of Candida spp. isolated from blood cultures. Mycopathologia 2007; 164: 265.17874282)
GokceGCerikciogluNYagciA. Acid proteinase, phospholipase, and biofilm production of Candida spp. isolated from blood cultures. Mycopathologia 2007; 164: 265.17874282GokceGCerikciogluNYagciA. Acid proteinase, phospholipase, and biofilm production of Candida spp. isolated from blood cultures. Mycopathologia 2007; 164: 265.17874282, GokceGCerikciogluNYagciA. Acid proteinase, phospholipase, and biofilm production of Candida spp. isolated from blood cultures. Mycopathologia 2007; 164: 265.17874282
E. Lyamuya, S. Aboud, W. Urassa, J. Sufi, J. Mbwana, F. Ndugulile, C. Massambu (2009)
Evaluation of simple rapid HIV assays and development of national rapid HIV test algorithms in Dar es Salaam, TanzaniaBMC Infectious Diseases, 9
Emmanuela Ambrose, J. Makani, N. Chami, T. Masoza, R. Kabyemera, R. Peck, Erasmus Kamugisha, A. Manjurano, Neema Kayange, L. Smart (2018)
High birth prevalence of sickle cell disease in Northwestern TanzaniaPediatric Blood & Cancer, 65
O. Hamza, M. Matee, M. Moshi, Elison Simon, F. Mugusi, Frans Mikx, Wim Helderman, A. Rijs, André Ven, P. Verweij (2008)
Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasisBMC Microbiology, 8
( NaglikJRRodgersCAShirlawPJ, et al. Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. J Infect Dis 2003; 188: 469–479.12870130)
NaglikJRRodgersCAShirlawPJ, et al. Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. J Infect Dis 2003; 188: 469–479.12870130NaglikJRRodgersCAShirlawPJ, et al. Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. J Infect Dis 2003; 188: 469–479.12870130, NaglikJRRodgersCAShirlawPJ, et al. Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections. J Infect Dis 2003; 188: 469–479.12870130
( NiimiMFirthNACannonRD. Antifungal drug resistance of oral fungi. Odontology 2010; 98: 15–25.20155503)
NiimiMFirthNACannonRD. Antifungal drug resistance of oral fungi. Odontology 2010; 98: 15–25.20155503NiimiMFirthNACannonRD. Antifungal drug resistance of oral fungi. Odontology 2010; 98: 15–25.20155503, NiimiMFirthNACannonRD. Antifungal drug resistance of oral fungi. Odontology 2010; 98: 15–25.20155503
M. Mushi, Benedictor Masewa, M. Jande, M. Mirambo, S. Mshana (2017)
Prevalence and factor associated with over-the-counter use of antifungal agents, in Mwanza City, TanzaniaTanzania journal of health research, 19
A. Howell, D. Isaacs, R. Halliday, The Infections (2009)
Oral nystatin prophylaxis and neonatal fungal infectionsArchives of Disease in Childhood: Fetal and Neonatal Edition, 94
S. Patil, Roopa Rao, Barnali Majumdar, S. Anil (2015)
Clinical Appearance of Oral Candida Infection and Therapeutic StrategiesFrontiers in Microbiology, 6
Fungal infections complicating pediatric AIDS
M. Mushi, Nathaniel Ngeta, M. Mirambo, S. Mshana (2018)
Predictors of esophageal candidiasis among patients attending endoscopy unit in a tertiary hospital, Tanzania: a retrospective cross-sectional studyAfrican Health Sciences, 18
( TsangCChuFLeungW, et al. Phospholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with type 2 diabetes mellitus. J Med Microbiol 2007; 56: 1393–1398.17893179)
TsangCChuFLeungW, et al. Phospholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with type 2 diabetes mellitus. J Med Microbiol 2007; 56: 1393–1398.17893179TsangCChuFLeungW, et al. Phospholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with type 2 diabetes mellitus. J Med Microbiol 2007; 56: 1393–1398.17893179, TsangCChuFLeungW, et al. Phospholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with type 2 diabetes mellitus. J Med Microbiol 2007; 56: 1393–1398.17893179
Smitha Raju, S. Rajappa (2011)
Isolation and Identification of Candida from the Oral CavityISRN Dentistry, 2011
P. Thanyasrisung, Piyanate Kesakomol, P. Pipattanagovit, P. Youngnak-Piboonratanakit, W. Pitiphat, O. Matangkasombut (2014)
Oral Candida carriage and immune status in Thai human immunodeficiency virus-infected individuals.Journal of medical microbiology, 63 Pt 5
( ArendrupMCCuenca-EstrellaMLass-FlörlC, et al. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. Clin Microbiol Infect 2012; 18: E246–E247.)
ArendrupMCCuenca-EstrellaMLass-FlörlC, et al. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. Clin Microbiol Infect 2012; 18: E246–E247.ArendrupMCCuenca-EstrellaMLass-FlörlC, et al. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. Clin Microbiol Infect 2012; 18: E246–E247., ArendrupMCCuenca-EstrellaMLass-FlörlC, et al. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. Clin Microbiol Infect 2012; 18: E246–E247.
( LyamuyaEFAboudSUrassaWK, et al. Evaluation of simple rapid HIV assays and development of national rapid HIV test algorithms in Dar es Salaam, Tanzania. BMC Infect Dis 2009; 9: 19.19226452)
LyamuyaEFAboudSUrassaWK, et al. Evaluation of simple rapid HIV assays and development of national rapid HIV test algorithms in Dar es Salaam, Tanzania. BMC Infect Dis 2009; 9: 19.19226452LyamuyaEFAboudSUrassaWK, et al. Evaluation of simple rapid HIV assays and development of national rapid HIV test algorithms in Dar es Salaam, Tanzania. BMC Infect Dis 2009; 9: 19.19226452, LyamuyaEFAboudSUrassaWK, et al. Evaluation of simple rapid HIV assays and development of national rapid HIV test algorithms in Dar es Salaam, Tanzania. BMC Infect Dis 2009; 9: 19.19226452
( StaibPLermannUBlass-WarmuthJ, et al. Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening. Antimicrob Agents Chemother 2008; 52: 146–156.17954688)
StaibPLermannUBlass-WarmuthJ, et al. Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening. Antimicrob Agents Chemother 2008; 52: 146–156.17954688StaibPLermannUBlass-WarmuthJ, et al. Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening. Antimicrob Agents Chemother 2008; 52: 146–156.17954688, StaibPLermannUBlass-WarmuthJ, et al. Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening. Antimicrob Agents Chemother 2008; 52: 146–156.17954688
( BlignautEMesserSHollisR, et al. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infect Dis 2002; 44: 169–174.12458124)
BlignautEMesserSHollisR, et al. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infect Dis 2002; 44: 169–174.12458124BlignautEMesserSHollisR, et al. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infect Dis 2002; 44: 169–174.12458124, BlignautEMesserSHollisR, et al. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infect Dis 2002; 44: 169–174.12458124
Gulce Gokce, N. Cerikcioglu, A. Yagci (2007)
Acid proteinase, phospholipase, and biofilm production of Candida species isolated from blood culturesMycopathologia, 164
( BlignautE. Oral candidiasis and oral yeast carriage among institutionalised South African paediatric HIV/AIDS patients. Mycopathologia 2007; 163: 67–73.17295100)
BlignautE. Oral candidiasis and oral yeast carriage among institutionalised South African paediatric HIV/AIDS patients. Mycopathologia 2007; 163: 67–73.17295100BlignautE. Oral candidiasis and oral yeast carriage among institutionalised South African paediatric HIV/AIDS patients. Mycopathologia 2007; 163: 67–73.17295100, BlignautE. Oral candidiasis and oral yeast carriage among institutionalised South African paediatric HIV/AIDS patients. Mycopathologia 2007; 163: 67–73.17295100
M. Ozturk, T. Gunes, E. Koklu, N. Çetin, N. Koç (2006)
Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care UnitMycoses, 49
E. Blignaut (2007)
Oral candidiasis and oral yeast carriage among institutionalised South African paediatric HIV/AIDS patientsMycopathologia, 163
E. Blignaut, S. Messer, R. Hollis, M. Pfaller (2002)
Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals.Diagnostic microbiology and infectious disease, 44 2
( HowellAIsaacsDHallidayR, et al. Oral nystatin prophylaxis and neonatal fungal infections. Arch Dis Child Fetal Neonatal Ed 2009; 94: F429–F433.)
HowellAIsaacsDHallidayR, et al. Oral nystatin prophylaxis and neonatal fungal infections. Arch Dis Child Fetal Neonatal Ed 2009; 94: F429–F433.HowellAIsaacsDHallidayR, et al. Oral nystatin prophylaxis and neonatal fungal infections. Arch Dis Child Fetal Neonatal Ed 2009; 94: F429–F433., HowellAIsaacsDHallidayR, et al. Oral nystatin prophylaxis and neonatal fungal infections. Arch Dis Child Fetal Neonatal Ed 2009; 94: F429–F433.
( MushiMFBaderOBiiC, et al. Virulence and susceptibility patterns of clinical Candida spp. isolates from a tertiary hospital, Tanzania. Med Mycol. Epub ahead of print 31 October 2018. DOI: 10.1093/mmy/myy107.)
MushiMFBaderOBiiC, et al. Virulence and susceptibility patterns of clinical Candida spp. isolates from a tertiary hospital, Tanzania. Med Mycol. Epub ahead of print 31 October 2018. DOI: 10.1093/mmy/myy107.MushiMFBaderOBiiC, et al. Virulence and susceptibility patterns of clinical Candida spp. isolates from a tertiary hospital, Tanzania. Med Mycol. Epub ahead of print 31 October 2018. DOI: 10.1093/mmy/myy107., MushiMFBaderOBiiC, et al. Virulence and susceptibility patterns of clinical Candida spp. isolates from a tertiary hospital, Tanzania. Med Mycol. Epub ahead of print 31 October 2018. DOI: 10.1093/mmy/myy107.
( BarchiesiFArzeniDDel PreteM, et al. Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis. J Antimicrob Chemother 1998; 41: 541–548.9630407)
BarchiesiFArzeniDDel PreteM, et al. Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis. J Antimicrob Chemother 1998; 41: 541–548.9630407BarchiesiFArzeniDDel PreteM, et al. Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis. J Antimicrob Chemother 1998; 41: 541–548.9630407, BarchiesiFArzeniDDel PreteM, et al. Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis. J Antimicrob Chemother 1998; 41: 541–548.9630407
( National AIDS Control Programme. National guidelines for the management of HIV and AIDS. New Delhi: Ministry of Health and Social Welfare, 2015.)
National AIDS Control Programme. National guidelines for the management of HIV and AIDS. New Delhi: Ministry of Health and Social Welfare, 2015.National AIDS Control Programme. National guidelines for the management of HIV and AIDS. New Delhi: Ministry of Health and Social Welfare, 2015., National AIDS Control Programme. National guidelines for the management of HIV and AIDS. New Delhi: Ministry of Health and Social Welfare, 2015.
( LattifAABanerjeeUPrasadR, et al. Susceptibility pattern and molecular type of species-specific Candida in oropharyngeal lesions of Indian human immunodeficiency virus-positive patients. J Clin Microbiol 2004; 42: 1260–1262.15004088)
LattifAABanerjeeUPrasadR, et al. Susceptibility pattern and molecular type of species-specific Candida in oropharyngeal lesions of Indian human immunodeficiency virus-positive patients. J Clin Microbiol 2004; 42: 1260–1262.15004088LattifAABanerjeeUPrasadR, et al. Susceptibility pattern and molecular type of species-specific Candida in oropharyngeal lesions of Indian human immunodeficiency virus-positive patients. J Clin Microbiol 2004; 42: 1260–1262.15004088, LattifAABanerjeeUPrasadR, et al. Susceptibility pattern and molecular type of species-specific Candida in oropharyngeal lesions of Indian human immunodeficiency virus-positive patients. J Clin Microbiol 2004; 42: 1260–1262.15004088
( WalshTButlerK. Fungal infections complicating pediatric AIDS. In: WilfertCPizzoPA (eds) Pediatric AIDS: the challenge of HIV infection in infants, children, and adolescents. Baltimore, MD: The Williams & Wilkins Co, 1991, pp.225–244.)
WalshTButlerK. Fungal infections complicating pediatric AIDS. In: WilfertCPizzoPA (eds) Pediatric AIDS: the challenge of HIV infection in infants, children, and adolescents. Baltimore, MD: The Williams & Wilkins Co, 1991, pp.225–244.WalshTButlerK. Fungal infections complicating pediatric AIDS. In: WilfertCPizzoPA (eds) Pediatric AIDS: the challenge of HIV infection in infants, children, and adolescents. Baltimore, MD: The Williams & Wilkins Co, 1991, pp.225–244., WalshTButlerK. Fungal infections complicating pediatric AIDS. In: WilfertCPizzoPA (eds) Pediatric AIDS: the challenge of HIV infection in infants, children, and adolescents. Baltimore, MD: The Williams & Wilkins Co, 1991, pp.225–244.
Ali Lattif, U. Banerjee, R. Prasad, A. Biswas, N. Wig, N. Sharma, A. Haque, N. Gupta, N. Baquer, G. Mukhopadhyay (2004)
Susceptibility Pattern and Molecular Type of Species-Specific Candida in Oropharyngeal Lesions of Indian Human Immunodeficiency Virus-Positive PatientsJournal of Clinical Microbiology, 42
C. Tsang, F. Chu, W. Leung, Lijian Jin, L. Samaranayake, S. Siu (2007)
Phospholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with type 2 diabetes mellitus.Journal of medical microbiology, 56 Pt 10
Background: Oral candidiasis (OC) is an indirect indicator of cell-mediated immunodeficiency with a high predictive value of disseminated candidiasis. Here, we report the prevalence and factors associated with laboratory-confirmed OC in human immunodeficiency virus (HIV)-uninfected children with clinical OC attending the outpatient clinic or admitted in pediatric wards of the Bugando Medical Center (BMC). Methods: A cross-sectional study was conducted between January and June 2017. Social demographic and clinical data were collected using a pre-tested data collection tool. Oral swabs were collected using a sterile cotton swab and mycological culture was done to detect Candida spp. followed by susceptibility testing as per European Committee on Antimicrobial Testing (EUCAST) guidelines. Data were analyzed using STATA version 13 following study objectives. Results: A total of 325 non-repetitive oral swabs from HIV-uninfected children aged between 2 and 156 months were collected. Candida spp. were detected in 123 (37.8%) children. One (1.8%) C. albicans isolate was resistant to fluconazole, voriconazole, and posaconazole with minimum inhibitory concentrations (MIC) of 256 μg/ml, 32 μg/ml, and 0.31 μg/ml, respectively. Upon multivariate logistic regression analysis, being a male child (OR 2, 95% CI 1.2–3.2, p = 0.008) and having a history of antibiotic use (OR 1.8, 95% CI 1.1–2.8, p = 0.017) independently predicted laboratory-confirmed OC among HIV-uninfected children. Conclusion: Only a third of children with clinical OC were laboratory confirmed, and this was more likely in male children with a history of antibiotic use. Most of the isolates were highly susceptible to commonly used antifungal agents like fluconazole. Treatment of children at risk should be prioritized to reduce associated morbidity.
Therapeutic Advances in Infectious Disease – SAGE
Published: May 20, 2021
Keywords: oral candidiasis; Antibiotic use; Limited fungi diagnosis; C. albicans
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.